home / stock / emmlf / emmlf news

EMMLF News and Press, OKYO Pharma Corp From 09/09/21

Stock Information
Company Name: OKYO Pharma Corp
Stock Symbol: EMMLF
Market: OTC
Menu
EMMLF EMMLF Quote EMMLF Short EMMLF News EMMLF Articles EMMLF Message Board
Get EMMLF Alerts

News, Short Squeeze, Breakout and More Instantly...
EMMLF - OKYO Pharma Limited ("OKYO" or the "Company") - Notice of Annual General Meeting

LONDON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO), the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that it will hold its annual ge...
EMMLF - OKYO Pharma Limited reports FY results

OKYO Pharma Limited (OTCQB:EMMLF): FY Total comprehensive loss of £2,99M Cash balance at 31 March 2021 of £4,99M vs. £190k a year ago. Press Release For further details see: OKYO Pharma Limited reports FY results

EMMLF - OKYO Pharma Limited Announces final audited results for the year ended 31 March 2021

LONDON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (the “Company”) is pleased to announce its final audited results for the year ended 31 March 2021. Summary of OKYO-101 studies during the last year OK-101 is designed to target a chemokine-like recep...

EMMLF - ("OKYO" or the "Company") - OKYO Pharma Retains Ora Inc. to Perform Regulatory Development of OK-101 for Dry Eye Indications

LONDON and BOSTON, June 29, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, is pleased to announce that it has retained the ser...
EMMLF - ("OKYO" or the "Company") - OKYO Pharma Announces Positive Data and Results in an Animal Model using Topically Administered OK-201 to Treat Neuropathic Ocular Pain

LONDON and BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, is pleased to announce positive results of OK-201,...

EMMLF - OKYO Pharma Limited ("OKYO" or the "Company") - OKYO announces appointment of Dr Rajkumar Patil as Chief Scientific Officer

LONDON, March 29, 2021 (GLOBE NEWSWIRE) -- OKYO (LSE: OKYO; OTCQB: EMMLF), the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, announces that it has appointed Dr Rajkumar Patil as Chi...

EMMLF - OKYO Pharma Limited ("OKYO" or the "Company") - Issue of Equity

LONDON, March 01, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited ("OKYO" or the "Company") today announces that it has issued 250,000 ordinary shares of no par value (" Ordinary Shares "), credited as fully paid, at a price of 4.5p per share on the exercise of 250,000 options. Applica...
EMMLF - OKYO Pharma has U.S. Patent Issued Covering its Lipid Conjugated Peptide Analogues for treating Ocular Pain and Inflammation

LONDON, Feb. 23, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited ("OKYO" or the "Company"), a biotechnology company focused on the development of novel drugs to treat inflammatory eye diseases and chronic ocular pain, today announced that patent No. 10,899,796 entitled “Compounds and Me...

EMMLF - OKYO Pharma Limited ("OKYO" or the "Company") - OKYO announces filing of a patent application covering the use of Chemerin and associated analogues to treat "cytokine storm" associated with COVID-19 and ARDS

LONDON and BOSTON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- OKYO (LSE: OKYO; OTCQB: EMMLF), the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, announces that it has today submitted a paten...

Previous 10 Next 10